https://www.selleckchem.com/pr....oducts/Tie2-kinase-i
As a result of limited clinical data, guidelines do not recommend the use of non-vitaminK antagonist oral anticoagulants in patients who weigh 120kg or have a body mass index (BMI) 40kg/m . This post hoc analysis of the AMPLIFY trial evaluated the efficacy (venous thromboembolism [VTE]/VTE-related death), safety (major and composite of major and clinically relevant non-major [CRNM] bleeding), and exposure of apixaban compared with enoxaparin followed by warfarin for the treatment of VTE by body weight (≤ 60,
Like
Comment
Share
